202 related articles for article (PubMed ID: 35343195)
1. Significance of emerging clinical oncology endpoints in support of overall survival.
Patil S; Agarwal V; Drupad HS
Indian J Cancer; 2022 Mar; 59(Supplement):S106-S118. PubMed ID: 35343195
[TBL] [Abstract][Full Text] [Related]
2. Surrogate endpoints for overall survival in digestive oncology trials: which candidates? A questionnaires survey among clinicians and methodologists.
Methy N; Bedenne L; Bonnetain F
BMC Cancer; 2010 Jun; 10():277. PubMed ID: 20537166
[TBL] [Abstract][Full Text] [Related]
3. Ovarian cancer clinical trial endpoints: Society of Gynecologic Oncology white paper.
Herzog TJ; Armstrong DK; Brady MF; Coleman RL; Einstein MH; Monk BJ; Mannel RS; Thigpen JT; Umpierre SA; Villella JA; Alvarez RD
Gynecol Oncol; 2014 Jan; 132(1):8-17. PubMed ID: 24239753
[TBL] [Abstract][Full Text] [Related]
4. Observations on Three Endpoint Properties and Their Relationship to Regulatory Outcomes of European Oncology Marketing Applications.
Liberti L; Stolk P; McAuslane JN; Schellens J; Breckenridge AM; Leufkens H
Oncologist; 2015 Jun; 20(6):683-91. PubMed ID: 25948678
[TBL] [Abstract][Full Text] [Related]
5. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
Chen EY; Joshi SK; Tran A; Prasad V
JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
[TBL] [Abstract][Full Text] [Related]
6. Review of meta-analyses evaluating surrogate endpoints for overall survival in oncology.
Sherrill B; Kaye JA; Sandin R; Cappelleri JC; Chen C
Onco Targets Ther; 2012; 5():287-96. PubMed ID: 23109809
[TBL] [Abstract][Full Text] [Related]
7. Endpoints in cancer clinical trials.
Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
[TBL] [Abstract][Full Text] [Related]
8. Immuno-oncology Trial Endpoints: Capturing Clinically Meaningful Activity.
Anagnostou V; Yarchoan M; Hansen AR; Wang H; Verde F; Sharon E; Collyar D; Chow LQM; Forde PM
Clin Cancer Res; 2017 Sep; 23(17):4959-4969. PubMed ID: 28864724
[TBL] [Abstract][Full Text] [Related]
9. The use of validated and nonvalidated surrogate endpoints in two European Medicines Agency expedited approval pathways: A cross-sectional study of products authorised 2011-2018.
Schuster Bruce C; Brhlikova P; Heath J; McGettigan P
PLoS Med; 2019 Sep; 16(9):e1002873. PubMed ID: 31504034
[TBL] [Abstract][Full Text] [Related]
10. Statistical considerations and endpoints for clinical lung cancer studies: Can progression free survival (PFS) substitute overall survival (OS) as a valid endpoint in clinical trials for advanced non-small-cell lung cancer?
Pilz LR; Manegold C; Schmid-Bindert G
Transl Lung Cancer Res; 2012 Mar; 1(1):26-35. PubMed ID: 25806152
[TBL] [Abstract][Full Text] [Related]
11. Association Between the Use of Surrogate Measures in Pivotal Trials and Health Technology Assessment Decisions: A Retrospective Analysis of NICE and CADTH Reviews of Cancer Drugs.
Pinto A; Naci H; Neez E; Mossialos E
Value Health; 2020 Mar; 23(3):319-327. PubMed ID: 32197727
[TBL] [Abstract][Full Text] [Related]
12. Searching for potential surrogate endpoints of overall survival in clinical trials for patients with prostate cancer.
Maeda H; Takeda K; Urushihara H; Kurokawa T
Cancer Rep (Hoboken); 2021 Jun; 4(3):e1334. PubMed ID: 33455091
[TBL] [Abstract][Full Text] [Related]
13. Surrogate endpoints for overall survival in advanced colorectal cancer: a clinician's perspective.
Piedbois P; Miller Croswell J
Stat Methods Med Res; 2008 Oct; 17(5):519-27. PubMed ID: 18285441
[TBL] [Abstract][Full Text] [Related]
14. Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?
Amir E; Seruga B; Kwong R; Tannock IF; Ocaña A
Eur J Cancer; 2012 Feb; 48(3):385-8. PubMed ID: 22115991
[TBL] [Abstract][Full Text] [Related]
15. Endpoints in paediatric oncology.
Paolucci P; Cioni V; Bigi E; Lucaccioni L; Cano C
Eur J Clin Pharmacol; 2011 May; 67 Suppl 1():33-40. PubMed ID: 21085937
[TBL] [Abstract][Full Text] [Related]
16. [Evaluation considerations for using surrogate endpoints in anticancer clinical trials].
Song YY; Tang L; Xia L; Hao RM; Yang ZM
Zhonghua Zhong Liu Za Zhi; 2022 Nov; 44(11):1155-1159. PubMed ID: 36380663
[TBL] [Abstract][Full Text] [Related]
17. A Primer on RECIST 1.1 for Oncologic Imaging in Clinical Drug Trials.
Ruchalski K; Braschi-Amirfarzan M; Douek M; Sai V; Gutierrez A; Dewan R; Goldin J
Radiol Imaging Cancer; 2021 May; 3(3):e210008. PubMed ID: 33988475
[TBL] [Abstract][Full Text] [Related]
18. Surrogate endpoints in oncology: when are they acceptable for regulatory and clinical decisions, and are they currently overused?
Kemp R; Prasad V
BMC Med; 2017 Jul; 15(1):134. PubMed ID: 28728605
[TBL] [Abstract][Full Text] [Related]
19. Clinical and outcome research in oncology. The need for integration.
Apolone G
Health Qual Life Outcomes; 2003 Apr; 1():3. PubMed ID: 12713667
[TBL] [Abstract][Full Text] [Related]
20. Progression-free survival as a surrogate for overall survival in oncology trials: a methodological systematic review.
Belin L; Tan A; De Rycke Y; Dechartres A
Br J Cancer; 2020 May; 122(11):1707-1714. PubMed ID: 32214230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
